Key terms
About MDGL
Madrigal Pharmaceuticals, Inc. engages on the development and commercialization of innovative therapeutic candidates for the treatment of cardiovascular, metabolic, and liver diseases. Its lead product, MGL-3196, is used for the treatment of non-alcoholic steatohepatitis and familial hypercholesterolemia. The company was founded by Rebecca Taub and Edward Chiang on September 2011 and is headquartered in Fort Washington, PA.
Sector
Industry
Employees
Founded
Website
Key stock statistics
1-day range
52-week range
Market cap
P/E ratio
Next earnings date
Dividend yield
Ex-dividend date
Dividend pay date
Key terms
Ad Feedback
Smart score
Latest MDGL news
Apr 09
8:15pm ET
Analysts Offer Insights on Healthcare Companies: Nurix Therapeutics (NRIX) and Madrigal Pharmaceuticals (MDGL)
Mar 25
6:50am ET
Analysts Conflicted on These Healthcare Names: Masimo (MASI), ImmunityBio (IBRX) and Madrigal Pharmaceuticals (MDGL)
Mar 20
8:13am ET
Madrigal Pharmaceuticals price target raised to $405 from $325 at Evercore ISI
Mar 19
5:58am ET
Madrigal Pharmaceuticals 750K share Spot Secondary priced at $260.00
Mar 19
2:00am ET
Analysts Are Bullish on These Healthcare Stocks: Cullinan Management (CGEM), Gilead Sciences (GILD)
Mar 18
4:05pm ET
Madrigal Pharmaceuticals announces $500M common stock offering
Mar 18
11:03am ET
Biotech Alert: Searches spiking for these stocks today
Mar 15
10:26am ET
BofA says 89bio should trade with strength after ‘win for entire MASH space’
Mar 15
9:41am ET
DoorDash upgraded, GM initiated: Wall Street’s top analyst calls
Mar 15
9:40am ET
Unusually active option classes on open March 15th
Mar 15
8:13am ET
Madrigal Pharmaceuticals price target raised to $410 from $337 at UBS
Mar 15
7:51am ET
Madrigal Pharmaceuticals price target raised to $375 from $320 at Oppenheimer
Mar 15
7:30am ET
Madrigal Pharmaceuticals price target raised to $390 from $349 at TD Cowen
Mar 15
7:17am ET
Approval of Madrigal’s Rezdiffra positive for Viking and MASH space, says Stifel
Mar 15
7:17am ET
Madrigal Pharmaceuticals price target raised to $377 from $338 at Canaccord
Mar 15
7:14am ET
Viking Therapeutics price target raised to $100 from $86 at BTIG
Mar 15
7:01am ET
Madrigal Pharmaceuticals price target raised to $389 from $382 at Citi
Mar 15
6:17am ET
Madrigal price target raised to $425 from $405 at H.C. Wainwright
Mar 15
6:12am ET
Madrigal Pharmaceuticals price target raised to $397 from $351 at JMP Securities
Mar 15
4:52am ET
Madrigal Pharmaceuticals upgraded to Neutral from Sell at B. Riley
Mar 14
4:45pm ET
Madrigal Pharmaceuticals trading resumes
Mar 14
4:37pm ET
Madrigal to resume trading at 4:45 PM ET after FDA approval
Mar 14
4:30pm ET
Madrigal label for Rezdiffra ‘best case scenario,’ say Piper Sandler
Mar 14
4:27pm ET
Madrigal announces FDA accelerated approval of Rezdiffra
Mar 14
3:47pm ET
FDA approves Madrigal Pharmaceuticals’ Rezdiffra
Mar 14
3:29pm ET
Madrigal Pharmaceuticals trading halted, news pending
Mar 12
6:25am ET
Buy Rating Affirmed for Madrigal Pharmaceuticals Amidst Resmetirom’s FDA Approval and First-Mover Advantage
Mar 12
6:17am ET
Madrigal Pharmaceuticals price target raised to $405 from $275 at H.C. Wainwright
Mar 08
8:00am ET
Analysts Are Bullish on These Healthcare Stocks: Prestige Consumer Healthcare (PBH), Madrigal Pharmaceuticals (MDGL)
Mar 08
7:44am ET
Madrigal Pharmaceuticals price target raised to $338 from $336 at Canaccord
Mar 07
7:41am ET
Analysts Offer Insights on Healthcare Companies: Madrigal Pharmaceuticals (MDGL), Biomea Fusion (BMEA) and Jasper Therapeutics (JSPR)
No recent press releases are available for MDGL
MDGL Financials
Key terms
Ad Feedback
MDGL Forecasts
analyst rating
- buy
- hold
- sell
1-year stock price forecast
MDGL Competitors
$ Market cap
P/E ratio
$ Price
1d change
52-week range